SCHEMBL6072367

SCHEMBL6072367

CCOc1cc2c(c3c1OC(C)(C)C3)C(c1ccc(C(=O)NC)c(NC(=O)c3ccccc3)c1)=NC(C)(C)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
CREBBP Q92793 1/20 0.39
GAA P10253 3/20 0.38
MAPT P10636 3/20 0.38
AHR P35869 1/20 0.37
POLB P06746 2/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PARP1 P09874 1/20 0.36
TP53 P04637 1/20 0.36
P4HTM Q9NXG6 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
ATM Q13315 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PTK2 Q05397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072931 0.95 HDAC1 (0.39) HDAC1HDAC8HDAC6CREBBPGAA
SCHEMBL6071949 0.93 HDAC1 (0.38) HDAC1HDAC8HDAC6CREBBPGAA
SCHEMBL6072342 0.93 HDAC1 (0.37) HDAC1HDAC8HDAC6GAAMAPT
SCHEMBL6072467 0.91 MAPT (0.42) HDAC1GAAMAPTAHRPOLB
SCHEMBL6072319 0.91 HTT (0.36) HDAC1HDAC8HDAC6GAAMAPT
SCHEMBL6072217 0.89 CREBBP (0.38) HDAC1HDAC8HDAC6CREBBPGAA
SCHEMBL6072017 0.88 KDM4E (0.44) HDAC1GAAMAPTPOLBALDH1A1
SCHEMBL6071789 0.87 GAA (0.35) HDAC1HDAC8HDAC6CREBBPGAA
SCHEMBL6072219 0.87 SMN1; SMN2 (0.39) HDAC1HDAC8HDAC6CREBBPMAPT
SCHEMBL6072405 0.86 PLK1 (0.37) HDAC1HDAC8HDAC6CREBBPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A HDAC1 122/4885HDAC8 539/4885HDAC6 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.